Press Releases Site - Investor Navigation Corporate Profile Press Releases Events & Presentations Stock Information Stock Quote & Chart Historic Price Lookup Analyst Coverage Financial Filings SEC Filings Corporate Governance Documents & Charters Management Team Board of Directors Investor Resources Investor FAQs Investor Email Alerts Contact IR Year None2022202120202019 Nov 28, 2022 Ikena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Update Nov 22, 2022 Ikena Oncology to Participate in the Piper Sandler 34th Annual Healthcare Conference Nov 10, 2022 Ikena Oncology Announces Initial Clinical Data from IK-175 Program in Urothelial Carcinoma Nov 07, 2022 Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update Oct 26, 2022 Ikena Oncology Presents Preclinical Data at the 34th EORTC-NCI-AACR Symposium on Novel TEAD Inhibitor, IK-930, Combating Therapeutic Resistance Oct 18, 2022 Ikena Oncology Provides Research & Development Update on IK-930 Program Targeting the Hippo Pathway Oct 05, 2022 Ikena Oncology to Present Initial Phase 1a/b Results from Novel AHR Inhibition Program at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting Sep 06, 2022 Ikena Oncology to Participate in September 2022 Investor Conferences Aug 11, 2022 Ikena Oncology Reports Second Quarter 2022 Financial Results and Provides a Corporate Update Jul 06, 2022 Ikena Oncology to Participate in the William Blair Biotech Focus Conference 2022 Pagination Current page 1 Page 2 Next page next › Last page last » Print Page Email Alerts RSS Feeds
Year None2022202120202019 Nov 28, 2022 Ikena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Update Nov 22, 2022 Ikena Oncology to Participate in the Piper Sandler 34th Annual Healthcare Conference Nov 10, 2022 Ikena Oncology Announces Initial Clinical Data from IK-175 Program in Urothelial Carcinoma Nov 07, 2022 Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update Oct 26, 2022 Ikena Oncology Presents Preclinical Data at the 34th EORTC-NCI-AACR Symposium on Novel TEAD Inhibitor, IK-930, Combating Therapeutic Resistance Oct 18, 2022 Ikena Oncology Provides Research & Development Update on IK-930 Program Targeting the Hippo Pathway Oct 05, 2022 Ikena Oncology to Present Initial Phase 1a/b Results from Novel AHR Inhibition Program at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting Sep 06, 2022 Ikena Oncology to Participate in September 2022 Investor Conferences Aug 11, 2022 Ikena Oncology Reports Second Quarter 2022 Financial Results and Provides a Corporate Update Jul 06, 2022 Ikena Oncology to Participate in the William Blair Biotech Focus Conference 2022 Pagination Current page 1 Page 2 Next page next › Last page last »
Nov 28, 2022 Ikena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Update
Nov 10, 2022 Ikena Oncology Announces Initial Clinical Data from IK-175 Program in Urothelial Carcinoma
Nov 07, 2022 Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
Oct 26, 2022 Ikena Oncology Presents Preclinical Data at the 34th EORTC-NCI-AACR Symposium on Novel TEAD Inhibitor, IK-930, Combating Therapeutic Resistance
Oct 18, 2022 Ikena Oncology Provides Research & Development Update on IK-930 Program Targeting the Hippo Pathway
Oct 05, 2022 Ikena Oncology to Present Initial Phase 1a/b Results from Novel AHR Inhibition Program at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
Aug 11, 2022 Ikena Oncology Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
